Aplagon Doses First Patient in Trial for Novel Limb-Saving Drug

HELSINKI, FINLAND – March 12, 2026 – By Sandra Patterson

Biotech firm Aplagon announced today it has dosed the first patient in a pivotal Phase 2a clinical trial for APAC, a first-in-class drug candidate aimed at treating a severe and often fatal circulatory condition. The ‘HEALING’ trial will investigate APAC's potential to treat Chronic Limb Threatening Ischemia (CLTI), the most advanced stage of Peripheral Arterial Occlusive Disease (PAOD), which carries a high risk of limb amputation and death.

This milestone moves the Helsinki-based company closer to offering a potential new lifeline for patients suffering from this devastating thrombo-inflammatory disease. The trial, approved by Finnish regulators (FIMEA), will enroll up to 42 patients and is designed to assess the safety and preliminary efficacy of the novel intravenous treatment.

The Devastating Toll of a Silent Disease

Chronic Limb Threatening Ischemia is the grim endgame for a significant portion of the millions affected by peripheral artery disease. Caused by severe blockage of arteries in the lower limbs, CLTI starves tissues of blood and oxygen. The prognosis is dire, with mortality rates reaching 25% within the first year of diagnosis—a figure that surpasses many common cancers. The five-year mortality rate can climb to a staggering 70%.

For survivors, the quality of life is often severely compromised by debilitating rest pain, non-healing ulcers, and gangrene. The risk of major limb amputation is exceptionally high, approaching 40% within six months for some patient groups. The primary risk factors, diabetes and smoking, are widespread, making CLTI a growing public health crisis. Current treatments, which focus on alleviating symptoms and re-establishing blood flow through invasive procedures, often fall short. A major challenge is restenosis—the re-narrowing of treated arteries—which occurs in roughly one-third of cases, leading to repeat procedures, immense patient suffering, and significant healthcare costs.

A Novel Approach to Thrombo-Inflammation

Aplagon's APAC is not just another anticoagulant; it represents a new therapeutic strategy. The drug is a 'heparin proteoglycan mimetic,' engineered to copy the body's natural defense mechanisms found in mast cells. This gives it a unique triple-action capability: it simultaneously functions as an antiplatelet, an anticoagulant, and a potent anti-inflammatory.

Crucially, APAC is designed to target and bind specifically to the site of vascular injury. This localized action promises to concentrate its therapeutic effects directly where they are needed most, potentially minimizing the systemic bleeding risks that plague many existing antithrombotic therapies. The approach stems from pioneering research conducted by Prof. Riitta Lassila and her team at the Wihuri Research Institute in Helsinki.

Maarit Venermo, Professor of vascular surgery at Helsinki University Hospital, commented on the drug's potential. “APAC has been shown to prevent platelet aggregation and blood clotting. Previous studies have also shown that it reduces the inflammatory response in tissues damaged by oxygen deprivation,” she stated. “Through these actions, APAC enhances the medical treatment of lower limb arterial atherosclerosis, accelerate the healing of tissue damage caused by ischemia, and prevent restenosis after revascularization procedures, thereby reducing the need for reinterventions.”

This multi-pronged attack on both the clotting (thrombosis) and inflammatory components of the disease is what sets APAC apart, offering a potential solution to the vexing problem of restenosis and microvascular dysfunction that limits the success of current interventions.

From Finnish Labs to the Global Stage

The initiation of the Phase 2a trial marks a significant clinical milestone for the Finnish biotech. “We’re delighted to have achieved this significant clinical milestone and dosed our first patient in our Phase 2a trial to treat PAOD/CLTI,” said Aki Prihti, CEO at Aplagon. “Our innovative approach, using a heparin proteoglycan mimetic with targeting ability and retention on the vascular injury sites, has potential applications across a broad range of serious vascular diseases caused by thrombo-inflammation.”

Investor confidence in this innovative approach is strong. Aplagon recently secured a €7 million financing round led by Nordic life science venture fund FSG Fund and the European Innovation Council (EIC) Fund, with participation from existing Finnish investors. This capital injection is funding the current CLTI trial and several other ongoing clinical studies, signaling robust belief in the company's technology and its potential to disrupt a market with a profound unmet need.

This financial backing and scientific validation underscore Aplagon's transition from a research-focused startup to a clinical-stage company poised to tackle a global health challenge. The company's progress highlights the strength of the Nordic biotech ecosystem in translating cutting-edge academic research into tangible clinical solutions.

Beyond CLTI, Aplagon is also leveraging its APAC platform to address other thrombo-inflammatory conditions. The company is planning a separate Phase 2 trial in 2026 to investigate APAC's use in preventing arteriovenous fistula (AVF) maturation failure in kidney dialysis patients, following a successful Phase 1 study. As the HEALING trial progresses, patients, physicians, and investors will be watching closely, hopeful that this novel Finnish innovation can change the devastating course of vascular disease.